In October 2025, the FDA updated Import Alert 66-66, emphasizing the need for accurate labeling of APIs to prevent misbranding.
In November 2025, the UK's Food Standards Agency (FSA) implemented the Genetic Technology (Precision Breeding) Regulations 2025, allowing businesses to apply for Precision Bred Organism (PBO) food and feed marketing authorizations. While this regulation primarily targets genetically modified organisms, it reflects the evolving regulatory landscape affecting dietary supplements. (food.gov.uk)
In December 2025, the European Medicines Agency (EMA) updated its guidelines on GMP compliance, reinforcing the importance of adhering to quality standards in pharmaceutical manufacturing. This update is pertinent to biotin manufacturers exporting to the EU, as compliance with GMP is mandatory for market access.
In January 2026, the WHO revised its pharmacopoeia standards, including updated monographs for vitamins such as biotin. These revisions aim to harmonize quality standards globally, impacting manufacturers and exporters of biotin supplements.
In February 2026, the Indian Ministry of Health and Family Welfare announced plans to review the classification of certain dietary supplements, including biotin, to ensure consumer safety and product efficacy. This initiative may lead to reclassification or additional regulatory requirements for biotin products in India.
